Trial record 2 of 749 for:    Smoking: Clinical Trials

Randomized Trial to Evaluate the Effectiveness of X-22 as a Smoking Cessation Aid

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2011 by 22nd Century Limited, LLC.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
22nd Century Limited, LLC
ClinicalTrials.gov Identifier:
NCT01400815
First received: July 19, 2011
Last updated: October 25, 2011
Last verified: October 2011
  Purpose

A randomized, active controlled clinical trial in which a total of 216 healthy smokers will be enrolled and followed over approximately 19 weeks.

The trial will evaluate the efficacy and safety of using X-22 as a smoking cessation aid.

Healthy smokers who plan to quit smoking will be screened for eligibility. Subjects will be randomized in a 1:1 ratio to 1 of the 2 treatment arms:

  • Group 1: X-22 Cigarettes (very low nicotine)
  • Group 2: Active Control Cigarettes The randomization will be stratified by gender. Efficacy will be assessed by analysis of cigarette consumption using self-report diaries and measurement of exhaled CO and cotinine concentrations.

Safety will be assessed by evaluation of adverse events, physical examinations, clinical laboratory tests, and measurement of heart rate, blood pressure, and body weight at each study visit.


Condition Intervention Phase
Smoking Cessation
Drug: X-22 Smoking Cessation Product
Drug: Active Control Cigarettes
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective, Double-blind, Randomized, Active Controlled, Parallel Group, Multicenter Phase II Clinical Trial to Evaluate the Effectiveness of X-22 as a Smoking Cessation Aid

Resource links provided by NLM:


Further study details as provided by 22nd Century Limited, LLC:

Primary Outcome Measures:
  • Efficacy - 4 weeks of continuous abstinence from smoking cigarettes [ Time Frame: 11 weeks ] [ Designated as safety issue: No ]
    The primary efficacy measurement is the number of subjects with 4 weeks of continuous abstinence from smoking cigarettes (Weeks 7-10), as assessed by subject diary and confirmed by exhaled CO, after treatment termination, at Visits 6 and 7.


Secondary Outcome Measures:
  • Secondary efficacy - point prevalence smoking abstinence [ Time Frame: 15 and 19 weeks ] [ Designated as safety issue: No ]
    Secondary efficacy measurements include 7-day point prevalence smoking abstinence rates at 2 and 3 months following treatment termination.

  • Secondary efficacy - withdrawal symptoms [ Time Frame: Weeks 7 through 19 ] [ Designated as safety issue: No ]
    Secondary efficacy measurements include withdrawal symptoms as measured by the Minnesota Nicotine Withdrawal Scale at each study visit

  • Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 19 weeks ] [ Designated as safety issue: Yes ]
    All AEs spontaneously reported, elicited, or observed by the investigators will be recorded at each study visit. Heart rate, blood pressure and body weight will be measured at each study visit. Physical examinations and urine pregnancy tests will be conducted at Screening and Visit 7. Clinical laboratory tests will be conducted at Screening and Visit 5.

  • Number of cigarettes smoked during the treatment period [ Time Frame: Weeks 2 through 6 ] [ Designated as safety issue: No ]
    The number of cigarettes smoked during the treatment period will be recorded and compared between active and placebo subjects.


Estimated Enrollment: 216
Study Start Date: July 2011
Estimated Study Completion Date: January 2012
Estimated Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: X-22 Smoking Cessation Product
The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.
Drug: X-22 Smoking Cessation Product

The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.

Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period.

Active Comparator: Active Control Cigarette
The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional "light" cigarette.
Drug: Active Control Cigarettes

The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional "light" cigarette.

Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period.


  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must meet all of the following inclusion criteria to be eligible for participation in this study.

    1. Subjects must be considered by the investigator to be in general good health and between 18 and 65 years of age, inclusive.
    2. Subjects must have a history of smoking at least 10 cigarettes per day for at least 1 year, with less than 3 months of abstinence during the past year, and a continuous smoking history for at least 3 months prior to study entry.
    3. Subjects must indicate that they plan to quit smoking within the next 3 months.
    4. Subjects must have a CO measurement of ≥ 10 ppm at screening and baseline (Visit 1 and Visit 2).
    5. Subjects must be willing and able to return for scheduled follow-up examinations for a total of 5 months.
    6. Female subjects must have been postmenopausal for the previous 6 months or be surgically sterile, or must have a negative pregnancy test and use one of the following acceptable methods of birth control for the duration of the study and for at least 3 months prior to screening:
  • abstinence, meaning a total lack of sexual activity,
  • oral contraceptives ("the pill"),
  • contraceptive injections,
  • intrauterine device,
  • double-barrier method (diaphragm or condom plus spermicidal cream),
  • contraceptive patch, hormonal implant, hormonal vaginal ring, or
  • male partner sterilization at least 3 months prior to screening. 7. Subjects must sign and be given a copy of the written Informed Consent form. 8. Subjects must be able to read, understand and complete the questionnaires independently.

Exclusion Criteria:

  • Subjects who meet any of the following exclusion criteria are not to be enrolled in this study.

    1. Subjects who have a household member who is already enrolled in this trial.
    2. Subjects who have attempted to quit smoking using one or more FDA-approved smoking cessation products (eg, NRT including nicotine gum, nicotine lozenges, nicotine patches, nicotine nasal spray, or nicotine inhaler; Zyban [bupropion]; or Chantix [varenicline]) for longer than 1 week in the past 3 months.
    3. Subjects who have been enrolled in another structured smoking cessation program (e.g., behavioral modification, hypnosis, acupuncture, or other alternative therapies) in the last 30 days.
    4. Subjects who have been in another smoking cessation trial in the past 6 months.
    5. Subjects who regularly use (greater than once per month) tobacco-based products other than cigarettes (eg, chew, snuff, snus, shisha, etc.).
    6. Subjects with a history of coronary artery disease, myocardial infarction, stroke, chronic obstructive pulmonary disease, or other significant pulmonary diseases. Controlled hypertensive subjects and mild asthmatics whose disease is controlled only with an as-needed inhaled beta agonist are acceptable.
    7. Subjects with a history of cancer within the past 60 months other than basal cell carcinoma.
    8. Subjects with a history of thromboembolic disease or taking warfin or any other anticoagulant, or anti-platelet drug such as clopidogrel (Plavix®) or pentoxifylline (Trental®). Low dose aspirin therapy is acceptable.
    9. Subjects with screening laboratory abnormalities that are considered by the investigator to be clinically significant.
    10. Subjects with a body mass index (BMI) >35.
    11. Subjects with poorly controlled diabetes or insulin-dependent diabetes.
    12. Subjects with other known serious pathophysiology or topical or systemic disorders of any kind that would confound the results of the study.
    13. Subjects with screening ECG abnormalities that are considered by the investigator to be clinically significant.
    14. Subjects who have used any illegal drug in the past 3 months.
    15. Subjects who have a positive urine drug screening result.
    16. Subjects who are pregnant or lactating, or who plan to become pregnant during the course of the study.
    17. Subjects participating in any other clinical trial of an investigational drug or device during the time of this clinical investigation or within 30 days prior to Screening visit.
    18. Subjects taking anti-depressants, anti-psychotics, clonidine, or any of the classes of drugs listed in the RapidCHECK® 12 Panel in the last 60 days (see Section 12.1.1).
    19. Subjects with systolic blood pressure over 140 mmHg and/or diastolic blood pressure over 90 mmHg.
    20. Subjects consuming an average of 3 or more drinks of alcohol per day.
    21. Subjects consuming greater than an average of 2 packs of cigarettes per day.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01400815

Locations
United States, California
Benchmark Research Sacramento
Sacramento, California, United States, 95816
United States, Louisiana
Benchmark Research New Orleans
Metairie, Louisiana, United States, 70006
United States, Texas
Benchmark Research Austin
Austin, Texas, United States, 78705
Sponsors and Collaborators
22nd Century Limited, LLC
  More Information

No publications provided

Responsible Party: 22nd Century Limited, LLC
ClinicalTrials.gov Identifier: NCT01400815     History of Changes
Other Study ID Numbers: X-22-201
Study First Received: July 19, 2011
Last Updated: October 25, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by 22nd Century Limited, LLC:
smoking
smoking cessation
quitting smoking

Additional relevant MeSH terms:
Smoking
Habits

ClinicalTrials.gov processed this record on July 29, 2014